A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties

Targeting PD1/PDL1 with blocking antibodies for cancer therapy has shown promising benefits in the clinic, but only approximately 20–30% of patients develop durable clinical responses to the treatment. Bispecific antibodies (BsAbs) that combine PD1/PDL1 blockade with the modulation of another immune...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jie Zhao, Liangfeng Jiang, Haodong Yang, Lan Deng, Xiaoqing Meng, Jian Ding, Sixing Yang, Le Zhao, Wei Xu, Xiaolong Wang, Zhenping Zhu, Haomin Huang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2022-12-01
coleção:	mAbs
Assuntos:	PD1 common light chain bispecific antibody linear Fab immunotherapy
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/19420862.2022.2044435
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!